Influence of biosimilar infliximab launch on the utilization pattern of biological medicines: the case of Hungary

References

• Morrow T, Felcone LH. Defining the difference: what makes biologics unique. Biotechnol Healthc. 2004;1(4):24–29.
   PubMedGoogle Scholar
• EMA [Internet]. Biosimilars in the EU – information guide for healthcare professionals. European Medicines Agency; [cited 2018 Jul 28]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/general/general_content_001832.jsp
   Google Scholar
• Bennett CL, Chen B, Hermanson T, et al. Regulatory and clinical considerations for biosimilar oncology drugs. Lancet Oncol. 2014 Dec;15(13):e594–e605.
   PubMed Web of Science ®Google Scholar
• GaBi Online [Internet]. Biologicals sales have almost doubled since 2006. Pro Pharma Communications International; [cited 2018 Jul 28]. Available from: http://www.gabionline.net/Biosimilars/General/Biologicals-sales-have-almost-doubled-since-2006
   Google Scholar
• PipelineReview.com [Internet]. Blockbuster biologics 2012. R&D Pipeline News, Special Edition 1/2013; [cited 2018 Jul 28]. Available from: https://pipelinereview.com/index.php/2013050850905/FREE-Reports/Blockbuster-Biologics-2012.html
   Google Scholar
• Aitken M. Delivering on the potential of biosimilar medicines. The role of functioning competitive markets. IMS Health; 2016.
   Google Scholar
• Aitken M. Outlook for global medicines through 2021. Balancing cost and value. QuintilesIMS Institute; 2016.
   Google Scholar
• IMS Health. Shaping the biosimilars opportunity: a global perspective on the evolving biosimilars landscape. IMS Health; 2011.
   Google Scholar
• DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22(2003):151–185.
   PubMed Web of Science ®Google Scholar
• Crommelin D, Bermejo T, Bissig M, et al. Pharmaceutical evaluation of biosimilars: important differences from generic low-molecular weight pharmaceuticals. Eur J Hosp Pharm. 2005;11(1):11–17.
   Google Scholar
• Moorkens E, Jonker-Exler C, Huys I, et al. Overcoming barriers to the market access of biosimilars in the European Union: the case of biosimilar monoclonal antibodies. Front Pharmacol. 2016;7:193.
   PubMed Web of Science ®Google Scholar
• Kawalec P, Stawowczyk E, Tesar T, et al. Pricing and reimbursement of biosimilars in central and eastern European countries. Front Pharmacol. 2017;8:288.
   PubMed Web of Science ®Google Scholar
• Kalo Z, Voko Z, Ostor A, et al. Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region. J Mark Access Health Policy. 2017;5(1):1345580.
   PubMedGoogle Scholar
• Inotai A, Csanadi M, Petrova G, et al. Patient access, unmet medical need, expected benefits, and concerns related to the utilisation of biosimilars in Eastern European countries: a survey of experts. Biomed Res Int. 2018;2018. p. 1–9. Article ID 9597362.
   PubMed Web of Science ®Google Scholar
• Jönsson B, Hofmarcher T, Lindgren P, et al. Comparator report on patient access to cancer medicines in Europe revisited. IHE Report. Lund: IHE; 2016:4.
   Google Scholar
• Kobelt G, Kasteng F. Access to innovative treatments in rheumatoid arthritis in Europe. European Federation of Pharmaceutical Industry Associations (EFPIA); 2009.
   Google Scholar
• Orlewska E, Ancuta I, Anic B, et al. Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries. Med Sci Monit. 2011 Apr;17(4):SR1–13.
   PubMed Web of Science ®Google Scholar
• GaBi Online [Internet]. Biologicals dominate Europe’s best sellers. Pro Pharma Communications International; [cited 2018 Jul 28]. Available from: http://www.gabionline.net/Reports/Biologicals-dominate-Europe-s-best-sellers
   Google Scholar
• GaBi Journal Editor. Patent expiry dates for biologicals: 2017 update. GaBI J. 2018;7(1):29–34.
   Google Scholar
• EMA. Biosimilars in the EU. Information guide for healthcare professionals. European Medicines Agency; 2017.
   Google Scholar
• EMA. Guideline on similar biological medicinal products. European Medicines Agency; 2014. CHMP/437/04 Rev.1.
   Google Scholar
• Lamanna WC, Holzmann J, Cohen HP, et al. Maintaining consistent quality and clinical performance of biopharmaceuticals. Exp Opin Biol Ther. 2018;18(4):369–379.
   PubMed Web of Science ®Google Scholar
• EMA, European Commission. Biosimilars in the EU. Information guide for healthcare professionals; [cited 2019 Sept 3]. Available from: https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf
   Google Scholar
• Inotai A, Prins CPJ, Csanadi M, et al. Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars. Exp Opin Biol Ther. 2017;17(8): 915–926.
   PubMed Web of Science ®Google Scholar
• Cohen HP, Blauvelt A, Rifkin RM, et al. Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes. Drugs. 2018 Mar;78(4):463–478.
   PubMed Web of Science ®Google Scholar
• Ebbers HC, Muenzberg M, Schellekens H. The safety of switching between therapeutic proteins. Expert Opin Biol Ther. 2012 Nov;12(11):1473–1485.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Chaparro M. Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: can it be recommended? A systematic review. Gastroenterol Hepatol. 2018 Jun - Jul;41(6):389–405.
   PubMed Web of Science ®Google Scholar
• NOR-SWITCH study group, Jorgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389(10086):2304–2316.
   PubMed Web of Science ®Google Scholar
• Kutzin J Health financing policy: a guide for decision-makers. Health (Financing Policy Paper 2008/1). WHO; 2008.
   Google Scholar
• WHO. The world health report 2000. Health systems: improving performance. WHO; 2000.
   Google Scholar
• Kalo Z, Holtorf AP, Alfonso-Cristancho R, et al. Need for multicriteria evaluation of generic drug policies. Value Health. 2015;18:346–351.
   PubMed Web of Science ®Google Scholar
• Aladul MI, Fitzpatrick RW, Chapman SR. Impact of infliximab and etanercept biosimilars on biological disease-modifying antirheumatic drugs utilisation and NHS budget in the UK. BioDrugs. 2017;31:533.
   PubMed Web of Science ®Google Scholar
• Elek P, Harsanyi A, Zelei T, et al. Policy objective of generic medicines from the investment perspective: the case of clopidogrel. Health Policy. 2017;121(2017):558–565.
   PubMed Web of Science ®Google Scholar
• Inotai A, Csanadi M, Harsanyi A, et al. Drug policy in Hungary. Value Health Reg Issues. 2017 Sep;13:16–22.
   PubMedGoogle Scholar
• EMA: Inflectra [Internet]. European Medicines Agency; [cited 2018 Jul 28]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/inflectra
   Google Scholar
• EMA: Remsima [Internet]. European Medicines Agency; [cited 2018 Jul 28]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/remsima
   Google Scholar
• EMA: Remicade – summary of product characteristics [Internet]. European Medicines Agency; [cited 2018 Jul 28]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000240/WC500050888.pdf
   Google Scholar
• Farkas K, Rutka M, Ferenci T, et al. Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn’s disease and ulcerative colitis – experiences from a single center. Exp Opin Biol Ther. 2017;17(11):1325–1332.
   PubMed Web of Science ®Google Scholar
• Balint A, Rutka M, Kolar M, et al. Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis – results from multicenter observational cohort. Exp Opin Biol Ther. 2018;18(11):1181–1187.
   PubMed Web of Science ®Google Scholar
• Public database on reimbursement submissions [Internet]. National Institute of Health Insurance Fund Management, Hungary; [cited 2018 Jul 28]. Available from: http://www.neak.gov.hu/felso_menu/szakmai_oldalak/gyogyszer_segedeszkoz_gyogyfurdo_tamogatas/egeszsegugyi_vallalkozasoknak/gyartok_forgalomba_hozok/KERELEM_IND_ELJ_GYOGYSZ_TAPSZ.html
   Google Scholar
• Inotai A, Csanadi M, Vitezic D, et al. Policy practices To maximise social benefit from biosimilars. J Bioequivalence Bioavailability. 2017;9:467–472
   Google Scholar
• James PA, Oparil S, Carter BL, et al. Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–520.
   PubMed Web of Science ®Google Scholar
• Davidson JR. Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry. 2010;71:e04.
   PubMedGoogle Scholar
• Sule A, Jorgensen F, Horak P, et al. Biosimilar medicines. Eur J Hosp Pharm. 2019 Mar;26(2):117–118.
   PubMedGoogle Scholar
• Giuliani R, Tabernero J, Cardoso F, et al. Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology. ESMO Open. 2019 Mar 6;4(2):e000460.
   PubMed Web of Science ®Google Scholar
• Leonard E, Wascovich M, Oskouei S, et al. Factors affecting health care provider knowledge and acceptance of biosimilar medicines: a systematic review. J Manag Care Spec Pharm. 2019 Jan;25(1):102–112.
   PubMed Web of Science ®Google Scholar